Brokerages predict that DENTSPLY SIRONA Inc. (NASDAQ:XRAY) will post earnings of $0.81 per share for the current quarter, according to Zacks Investment Research. Eight analysts have made estimates for DENTSPLY SIRONA’s earnings. The highest EPS estimate is $0.82 and the lowest is $0.80. DENTSPLY SIRONA posted earnings of $0.67 per share in the same quarter last year, which suggests a positive year over year growth rate of 20.9%. The business is scheduled to report its next quarterly earnings results on Friday, February 16th.
On average, analysts expect that DENTSPLY SIRONA will report full year earnings of $2.65 per share for the current fiscal year, with EPS estimates ranging from $2.65 to $2.66. For the next financial year, analysts expect that the firm will post earnings of $2.93 per share, with EPS estimates ranging from $2.80 to $3.07. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for DENTSPLY SIRONA.
DENTSPLY SIRONA (NASDAQ:XRAY) last issued its earnings results on Friday, November 3rd. The medical instruments supplier reported $0.70 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.66 by $0.04. DENTSPLY SIRONA had a positive return on equity of 7.56% and a negative net margin of 20.33%. The business had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $978.99 million. During the same period in the prior year, the firm posted $0.66 EPS. DENTSPLY SIRONA’s quarterly revenue was up 5.8% compared to the same quarter last year.
XRAY has been the subject of a number of recent research reports. Zacks Investment Research cut DENTSPLY SIRONA from a “hold” rating to a “sell” rating in a report on Monday, October 30th. Jefferies Group decreased their price objective on DENTSPLY SIRONA from $72.00 to $66.00 and set a “buy” rating on the stock in a research report on Wednesday, August 23rd. Cleveland Research lowered DENTSPLY SIRONA from a “buy” rating to a “neutral” rating in a research report on Thursday, October 5th. BidaskClub lowered DENTSPLY SIRONA from a “strong-buy” rating to a “buy” rating in a research report on Saturday, December 2nd. Finally, HC Wainwright restated a “buy” rating and issued a $68.00 price target on shares of DENTSPLY SIRONA in a research report on Tuesday, October 3rd. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and nine have issued a buy rating to the stock. DENTSPLY SIRONA has an average rating of “Buy” and an average target price of $68.83.
In other news, Director Francis J. Lunger sold 8,900 shares of DENTSPLY SIRONA stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $65.90, for a total value of $586,510.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Nicholas W. Alexos acquired 50,000 shares of the stock in a transaction on Monday, November 13th. The shares were purchased at an average price of $65.85 per share, with a total value of $3,292,500.00. The disclosure for this purchase can be found here. Insiders own 1.99% of the company’s stock.
Several large investors have recently made changes to their positions in the company. Bessemer Group Inc. boosted its position in DENTSPLY SIRONA by 4,638.6% during the third quarter. Bessemer Group Inc. now owns 1,903,596 shares of the medical instruments supplier’s stock valued at $113,855,000 after acquiring an additional 1,863,424 shares during the last quarter. Alyeska Investment Group L.P. raised its holdings in shares of DENTSPLY SIRONA by 223.7% in the 3rd quarter. Alyeska Investment Group L.P. now owns 2,271,534 shares of the medical instruments supplier’s stock worth $135,860,000 after acquiring an additional 1,569,746 shares during the last quarter. Principal Financial Group Inc. raised its holdings in shares of DENTSPLY SIRONA by 22.3% in the 2nd quarter. Principal Financial Group Inc. now owns 6,474,432 shares of the medical instruments supplier’s stock worth $419,802,000 after acquiring an additional 1,181,547 shares during the last quarter. Jackson Square Partners LLC raised its holdings in shares of DENTSPLY SIRONA by 15.6% in the 3rd quarter. Jackson Square Partners LLC now owns 6,334,906 shares of the medical instruments supplier’s stock worth $378,890,000 after acquiring an additional 855,199 shares during the last quarter. Finally, Parnassus Investments CA raised its holdings in shares of DENTSPLY SIRONA by 62.7% in the 3rd quarter. Parnassus Investments CA now owns 2,115,000 shares of the medical instruments supplier’s stock worth $126,498,000 after acquiring an additional 815,000 shares during the last quarter. Institutional investors own 96.58% of the company’s stock.
DENTSPLY SIRONA (XRAY) opened at $64.90 on Monday. DENTSPLY SIRONA has a twelve month low of $52.53 and a twelve month high of $68.98. The company has a quick ratio of 1.59, a current ratio of 2.32 and a debt-to-equity ratio of 0.21. The stock has a market capitalization of $14,910.00, a P/E ratio of 25.86, a PEG ratio of 2.57 and a beta of 1.31.
ILLEGAL ACTIVITY WARNING: This news story was first reported by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are accessing this news story on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be accessed at https://www.truebluetribune.com/2018/01/03/zacks-brokerages-expect-dentsply-sirona-inc-xray-will-post-earnings-of-0-81-per-share.html.
About DENTSPLY SIRONA
DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DENTSPLY SIRONA Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA Inc. and related companies with MarketBeat.com's FREE daily email newsletter.